Tissue manipulation systems and methods of use thereof

By using a cutter actuator and a handle body system with the filling port in the prostate urethra, combined with elongated members and expandable members, minimally invasive treatment of benign prostatic hyperplasia is achieved, solving excessive tissue damage in traditional surgery Problem, a low-risk BPH treatment regimen is provided.

CN118984680APending Publication Date: 2024-11-19TELEFLEX LIFE SCIENCES LLC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380029298.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-06-10
Filing Date
2023-03-20
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

The prior art is difficult to effectively treat urinary flow obstruction caused by benign prostate hyperplasia (BPH) through minimally invasive and low-risk means, and traditional surgery may lead to excessive tissue damage and complications.

Method used

A handle body system including a cutter actuator and a filling port is designed. Through an elongated member and an expandable member, it can stably cut tissue and deliver therapeutic substances in the prostate urethra to achieve minimally invasive tissue manipulation and treatment. .

Benefits of technology

The system enables the relief of BPH symptoms with minimal tissue damage, provides a minimally invasive and low-risk treatment option, reduces the risk of postoperative complications, and improves urinary flow through cutting and delivery of therapeutic substances.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118984680A_ABST
    Figure CN118984680A_ABST
Patent Text Reader

Abstract

Devices, systems, and related methods for cutting, manipulating, and stabilizing tissue are disclosed. A system for manipulating tissue in a prostatic urethra includes a handle body (110) having a deployment or cutting actuator (112) and a charging port (116). An elongate member (150) is coupled to the distal end of the handle body, and an expandable member (180) is coupled to the distal end of the elongate member, which also includes a delivery body or cutter body. The expandable member is configured to stably abut the delivery body or cutter body against target tissue when the expandable member is expanded. A tissue manipulation structure (e.g., a cutter (172)) is configured to move from a first position to a second position in which at least a portion of the structure extends into surrounding prostate tissue.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Patent Application Serial No. 63 / 322,662, filed on March 23, 2022, and entitled “TISSUE CUTTING SYSTEM AND METHODS OF USE,” and U.S. Provisional Patent Application Serial No. 63 / 350,929, filed on June 10, 2022, and entitled “TISSUE MANIPULATING SYSTEM AND METHODS OF USE,” both of which are incorporated herein by reference in their entirety. Technical Field

[0002] The present disclosure relates generally to medical devices and methods, and more particularly to systems and related methods for manipulating, cutting and / or retracting tissue and anatomical or other structures within a human or animal subject to treat a disease or disorder, such as a prostate condition. Background Art

[0003] An example of a condition that requires manipulation or retraction of tissue is benign prostatic hyperplasia (BPH). BPH is one of the most common diseases affecting men, especially older men. It is reported that more than half of men in the United States will have histopathological evidence of BPH by the age of 60, and approximately 9 in 10 men have the disease by the age of 85. Furthermore, as the average age of the population in developed countries increases, the incidence and prevalence of BPH are expected to increase.

[0004] Some BPH treatments require access to the urinary tract. New devices and methods have been developed for various procedures to manipulate or retract prostate tissue, either alone or in conjunction with BPH treatments. Some procedures remove tissue, while others alter it.

[0005] One example of a surgical procedure to treat symptoms of BPH is a transurethral incision of the prostate (TUIP). In this procedure, resistance to urine flow is reduced by making one or more incisions through the prostate in the area where the urethra and bladder meet, called the bladder neck. This procedure is done under general or spinal anesthesia. In this procedure, one or more incisions are made through the bladder neck muscle. Most of the time, the incisions are deep enough to cut through the surrounding prostate tissue, including the prostate capsule. This will release any pressure on the bladder neck and allow the bladder neck to pop open. The incisions may be made using a resectoscope, a laser beam, or other methods.

[0006] Another interesting approach is to use a drug-coated balloon to dilate the urethra in the area of ​​the prostatic urethra. The drug-coated balloon expands and causes damage to at least the invaded tissue and may cause damage to the underlying tissue. In a typical balloon procedure, tissue along the entire inner periphery of the prostatic urethra is damaged by the expanding balloon. The drug coating on the balloon helps mitigate the hyperproliferative healing response, making the prostatic urethra less obstructed than before the procedure. However, this procedure may cause more tissue damage than is necessary to treat the symptoms of BPH. Summary of the invention

[0007] The present inventors recognized that there remains a need for minimally invasive and low risk methods to treat the minimum amount of tissue required to relieve symptoms of BPH. The present disclosure meets these needs.

[0008] Various aspects of the present disclosure are directed to systems and methods for treating, manipulating, and stabilizing tissue within the prostatic urethra to improve symptoms of BPH. Certain embodiments are directed to treating tissue within the prostatic urethra by cutting the tissue and delivering a therapeutic substance.

[0009] Embodiments of the present disclosure relate to a system for treating tissue in the prostatic urethra, including a handle body having a cutter actuator and a filling port. Embodiments of the system may also include an elongated member coupled to the distal end of the handle body and the cutter body. An expandable member may be coupled to the distal end of the elongated member. The expandable member may be configured to stabilize the cutter body against the target tissue when the expandable member is expanded. The cutter may be configured to move from a first position in the cutter body to a second position protruding from the cutter slot and again to a third position in the cutter body. An injection port on the handle body that is in fluid communication with the cutter slot may be configured to supply a therapeutic substance to the target tissue through the cutter slot.

[0010] Embodiments of the present disclosure relate to systems for manipulating tissue in the prostatic urethra, including a handle body having a deployment actuator and a charging port. Embodiments of the system may include an elongated member coupled to the distal end of the handle body. The system may include a conveying body and an expandable member coupled to the distal end of the elongated member. The expandable member may be configured to stabilize the conveying body relative to the target tissue when it expands. The tissue manipulation structure may be configured to move from a first position in the conveying body to a second position at least partially within the prostatic tissue. The movement of the tissue manipulation structure may be controlled by the deployment actuator.

[0011] Other features and advantages of various embodiments of the present invention will become apparent from the following description in conjunction with the accompanying drawings, which illustrate certain principles of the present invention by way of example. These illustrative aspects are not intended to limit or define the present disclosure, but to provide examples to aid understanding of the present disclosure. BRIEF DESCRIPTION OF THE DRAWINGS

[0012] The features, aspects, and advantages of the present disclosure may be better understood when the following detailed description is read with reference to the accompanying drawings. In the drawings, the same reference numerals may be used to describe similar features and components in multiple drawings. The accompanying drawings generally illustrate, by way of example (but not by way of limitation), the various apparatus and method aspects discussed in this patent document.

[0013] Figure 1 is a cross-sectional view showing the anatomical structures surrounding the prostate of a human subject.

[0014] Figure 2 is a view of the tissues lining the prostatic urethra.

[0015] Figure 3 is a perspective view of a system according to various aspects of the present disclosure.

[0016] Figure 4A is a perspective view of a distal portion of a system according to various aspects of the present disclosure.

[0017] Figure 4B is a perspective view of a distal portion of a system according to various aspects of the present disclosure.

[0018] Figure 5 is a perspective view of a distal portion of a system according to various aspects of the present disclosure.

[0019] Fig. 6A is a partially transparent side view of a distal portion of a system according to various aspects of the present disclosure.

[0020] Figure 6B is a partially transparent side view of a distal portion of a system according to various aspects of the present disclosure.

[0021] Figure 6C is a partially transparent side view of a distal portion of a system according to various aspects of the present disclosure.

[0022] Fig.6D is a partially transparent side view of a distal portion of a system according to various aspects of the present disclosure.

[0023] Fig. 6E is a perspective view of a distal portion of a system according to various aspects of the present disclosure.

[0024] Fig. 7A is a plan view of a proximal portion of a system according to various aspects of the present disclosure.

[0025] Figure 7B is a plan view of a proximal portion of a system according to various aspects of the present disclosure.

[0026] Fig. 8Ais a perspective view of a proximal portion of a system according to various aspects of the present disclosure.

[0027] Figure 8B is a perspective view of a proximal portion of a system according to various aspects of the present disclosure.

[0028] Fig. 9A is a flow chart illustrating steps in a method of using a system according to various aspects of the present disclosure.

[0029] Fig. 9B is a flow chart illustrating steps in another method of using the system according to various aspects of the present disclosure.

[0030] Fig.10 is a perspective view of another system according to various aspects of the present disclosure.

[0031] Fig.11 is a perspective view of a system according to various aspects of the present disclosure.

[0032] Fig.12 is a perspective view of a tissue manipulation structure according to various aspects of the present disclosure.

[0033] Fig.13 is a perspective view of a distal portion of a system according to various aspects of the present disclosure.

[0034] Fig.14 is a perspective view of a distal portion of a system according to various aspects of the present disclosure.

[0035] Fig.15 is a partially transparent side view of a distal portion of a system according to various aspects of the present disclosure.

[0036] Fig.16A is a flow chart illustrating steps in a method of using a system according to various aspects of the present disclosure.

[0037] Fig. 16B is a flow chart illustrating steps in another method of using a system according to various aspects of the present disclosure. DETAILED DESCRIPTION

[0038] Many specific details are set forth herein in order to provide a comprehensive understanding of the claimed subject matter. However, those skilled in the art will appreciate that the claimed subject matter may be practiced without these specific details. In other cases, methods, devices, or systems known to those skilled in the art are not described in detail in order to avoid obscuring the claimed subject matter.

[0039] As used herein, "adapted to" or "configured to" is intended to be open and inclusive language and does not exclude devices adapted or configured to perform additional tasks or steps. As used herein, "proximal" and "distal" refer to relative positions relative to a user of an elongated minimally invasive device, where "proximal" means relatively toward the user and "distal" means relatively away from the user. The headings, lists, and numbers included herein are for convenience of explanation only and are not intended to be limiting.

[0040] As used herein, the term "manipulation" may refer to "cutting," "pulling," and / or "stabilizing" tissue. In other examples, "manipulation" may refer to an activity that is different from terms such as "cutting." For example, cutting tissue may refer to using Figure 3 The system 100 shown in FIG. 1 is used to slice tissue, while manipulating tissue may refer to using Fig.10 and / or the system shown in 11 to create and / or stabilize an opening in the commissure.

[0041] Figure 1 is a cross-sectional view showing the anatomy surrounding the prostate gland of a human subject. The prostate gland PG is a walnut-sized muscular gland located near the bladder UB. The urethra UT runs through the prostate gland PG. The prostate gland PG secretes fluids to protect and nourish the sperm. The prostate gland PG also contracts during ejaculation, expelling semen and providing a valve to prevent urine from entering the semen. The bladder UB holds urine. The vas deferens (VD) defines a duct that carries semen, while the seminal vesicles secrete semen. The rectum R is the end of the large intestine, through which waste products are expelled. The urethra UT carries urine and semen out of the body. Therefore, the urethra is connected to the bladder UB and provides a passage for the vas deferens VD and the seminal vesicles. In addition, the triangular T is the smooth, triangular end of the bladder. It is sensitive to distension and signals the brain when the bladder (UB) is full. The caruncle is a bulge on the wall of the urethra UT where the sperm ducts enter. The prostate gland urethra is the portion of the urethra UT that extends through the prostate gland.

[0042] The prostate can be described by its prostatic lobes. The regional classification is often used in pathology, while the lobe classification is more commonly used in anatomy. The central region of the prostatic PG accounts for approximately 25% of the normal prostate and this region surrounds the ejaculatory ducts. The transition zone presents some degree of benign prostatic hyperplasia. The fibromuscular zone typically has no glandular components and, as the name implies, is composed only of muscle and fibrous tissue. The transition zone typically covers the proximal urethra and is the area where the glands grow throughout life. Furthermore, this lobe is often associated with benign prostatic enlargement. Finally, the peripheral zone is the subcapsular portion of the posterior prostate that surrounds the distal urethra.

[0043] The lobe characterization is different from the regional characterization, but there is some overlap. The anterior lobe has no glandular tissue and is formed entirely of fibromuscular tissue. Therefore, this lobe corresponds roughly to the anterior portion of the transition zone. The posterior lobe corresponds roughly to the peripheral zone and can be palpated through the rectum during a digital rectal examination. The posterior lobe is the site of 70-80% of prostate cancers. The lateral lobe is the main mass of the prostate and is separated by the urethra. It is described as spanning all zones. Finally, the middle lobe corresponds roughly to a portion of the central zone. It varies greatly in size and in some cases lacks glandular tissue.

[0044] Near the front inner side of the urethra, there is a commissure where each leaf adjoins each other. In certain aspects of the present disclosure, the system and method are directed to cutting, manipulating and / or stabilizing tissue at the commissure. Embodiments may further relate to applying a therapeutic substance to the commissure, such as at the incision site. The cut, manipulated and / or stabilized tissue at the commissure can provide an opening in the originally limited prostatic urethra so that the fluid pressure from the bladder can allow urine to flow through the prostatic urethra. In various examples, the estimated commissure length may range from about 10 mm to about 50 mm, with a typical length range of 25 ± 5 mm. Commissures of various lengths can be manipulated and treated according to the examples described herein.

[0045] Figure 2 is a view of the tissues lining the prostatic urethra. Figure 2 The two lateral lobes of the prostate PG are shown adjoining each other to define the commissure C. Figure 2 The cross-sectional area of ​​the prostate portion of the urethra UT shown in FIG. 1 is significantly reduced due to the compression of the prostate. Figure 2 Illustrations of prostate tissue that requires cutting, manipulation, and / or stabilization by the systems and methods disclosed herein are shown.

[0046] Figure 3 1 is a perspective view of a system according to various aspects of the present disclosure. The system 100 is shown coupled to the endoscope body 200 at the proximal end of the handle body 110 of the system 100. The handle body 110 includes an actuator 112 operably connected to the distal portion 160 of the system 100. Specifically, the actuator 112 can be operably connected to the cutter in the distal portion 160 of the system 100, and may therefore be referred to as a "cutter actuator" in various embodiments. The handle body 110 in the illustrated example also includes a lock 115 engaged with the actuator 112 to lock or unlock the actuator 112. The lock 115 can engage the actuator 112 to lock it, so that the lock 115 prevents the actuator 112 from being operated when it is in the locked position, thereby preventing the cutter movement described herein. Conversely, the lock 115 can disengage the actuator 112 to unlock it and allow the actuator to operate from the unlocked position.

[0047] Figure 3The handle body 110 in the illustrated example includes a charging port 116 and an injection port 118. Both the charging port 116 and the injection port 118 are configured to deliver fluid to a distal portion 160 of the system. The charging port 116 is configured to deliver the filling fluid to the distal portion 160 of the system 100 through a charging lumen within the handle body 110 and within the elongated member 150 of the system. Similarly, the injection port 118 is configured to deliver the injection fluid to the distal portion 160 of the system 100 through an injection lumen within the handle body 110 and within the elongated member 150 of the system. In some examples of the system 100, the injection lumen is also the lumen through which the cutter wire is connected between the actuator 112 and the distal portion 160.

[0048] The elongated member 150 connects the handle body 110 to the distal portion 160. The elongated member 150 may include an endoscope lumen for an elongated portion of an endoscope configured for use within a patient. The elongated member 150 may also include the previously described filling lumen and injection lumen. In some examples of the system, the elongated member 150 includes a cutter wire located within the injection lumen, and in other examples, the cutter wire occupies a space within the elongated member 150 that is separate from the injection lumen. The elongated member 150 may be rigid, semi-rigid, or semi-flexible. The elongated member 150 is configured to be inserted into the urethra of a patient and is constructed of a material suitable for medical use.

[0049] Figure 4A and Figure 4B 1 are perspective views of distal portions of the system 100 according to various aspects of the present disclosure. In the example shown, the elongated member 150 of the system is connected to the cutter body 170 and the expandable member 180 via a bend or hinge 165 (or "hinge portion"). An endoscope distal end 205 can be seen at the distal end of the elongated member 150. In this non-limiting example, the endoscope distal end 205 is a 30 degree cystoscope. Additional endoscopes may be used.

[0050] Beyond the distal end of the elongated member 150 is a hinge 165, which may be more flexible than the elongated member 150. The hinge 165 may be configured to bend at a preformed angle relative to the long axis of the elongated member 150. The preformed curve in the hinge 165 may be configured to roughly match the typical anatomical curvature of the urethra near the prostate and bladder neck. The hinge 165 may be flexible so that the hinge 165 can conform to the curvature of the urethra and position the distal portion 160 in the prostatic urethra without piercing the urethral wall. The hinge 165 enables the cutter body 170 to be easily seen by a 30 degree cystoscope. The hinge 165 may be made of plastic, shape memory material, or other flexible to semi-flexible material suitable for medical use. Compared to a completely rigid device, the flexibility of the hinge 165 allows for relatively easy navigation of the urethra and allows the cutter body 170 to be at an ideal angle relative to the long axis of the elongated member 150 within the anatomical structure. Articulation 165 may include an inflation lumen, an injection lumen, and a cutter wire.

[0051] Cutter body 170 and expandable member 180 cooperate to extend a cutter (e.g., Fig. 6A , 6B , 6C and 6D) is placed in a correct position within the prostatic urethra, for example, facing the target prostatic lobe that compresses the urethra. Figure 4B Shown with Figure 4A 100. The expandable member 180 is shown in the expanded state compared to the unexpanded state shown in FIG. When the cutter body 170 is placed in the desired position in the prostatic urethra, the expandable member 180 is expanded to push the cutter body 170 toward the prostatic urethra. The expandable member 180 ensures that there is enough contact between the cutter body 170 and the prostatic tissue so that the cutter can cut the tissue. The expansion and contraction of the expandable member 180 can be controlled by the filling fluid conducted through the filling cavity from the filling port on the handle body 110 of the system 100.

[0052] Figure 51 is a perspective view of the distal portion of a system according to various aspects of the present disclosure. In this view, the surface of the cutter body 170 facing the tissue to be treated is shown. The cutter body 170 includes a cutter slot 175, which provides access to the tissue for a cutter (e.g., cutter 172) and an injectable substance (not shown). The length of the cutter slot 175 may be about 1.0 cm to about 10 cm, including less than about 1.0 cm or about 1.5 cm, about 2.0 cm, about 2.5 cm, about 3.0 cm, about 3.5 cm, about 4.0 cm, about 4.5 cm, about 5.0 cm, about 5.5 cm, about 6.0 cm, about 6.5 cm, about 7.0 cm, about 7.5 cm, about 8.0 cm, about 8.5 cm, about 9.0 cm, about 9.5 cm or greater than 10.0 cm. In some examples, the length of the cutter slot 175 is preferably about 5.0 cm. The cutter slot 175 may occupy a significant portion of the tissue-facing surface of the cutter body 170, for example greater than or approximately equal to about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, or about 95% or more of the length of the cutter body 170.

[0053] Figure 5 It is shown that hinge 165 can be flexible so that cutter body 170 can be positioned along the same axis as elongated member 150, for example, if necessary to accommodate the geometry of the relevant anatomical structure. Thus, the flexibility of hinge 165 can allow it to assume a variety of curvatures (including zero degrees) to accommodate various anatomical features. In some examples, hinge 165 can be biased to a particular configuration, such as straight or curved.

[0054] Fig. 6A , 6B , 6C and 6D respectively show a partially transparent side view of the distal portion of the system according to various aspects of the present disclosure. In addition to the expandable member 180 and the cutter body 170, Fig. 6A , 6B , 6C and 6D also show a cutter 172, a cutter distal recess 176, a cutter track 177 and a cutter proximal recess 178. The cutter 172, the cutter distal recess 176, the cutter track 177 and the cutter proximal recess 178 cooperate to achieve controlled cutting of tissue when the cutter 172 is pulled proximally by the cutter wire via operation of the actuator 112 on the handle body 110. Fig. 6A , 6B, 6C and 6D respectively show a cutter 172 having a distal lobe 181 and a proximal lobe 182, but other cutter shapes are also desirable and advantageous as long as they enable the cutter 172 to be located within the cutter body 170 and at least partially exposed from the cutter body 170 when the cutter 172 is actuated.

[0055] exist Fig. 6A In the embodiment of the present invention, the cutter 172 is at least partially positioned in the cutter distal recess 176 so that no portion of the cutter 172 partially passes through the cutter slot 175. When the cutter 172 is at least partially positioned in the cutter distal recess 176, the cutter body 170 can be safely introduced into a tissue lumen (e.g., a urethra) and positioned at a desired treatment site (e.g., within the prostatic urethra). In some aspects, the cutter slot 175 includes a cutter slot distal lip 173 to help secure the cutter 172 in the cutter distal recess 176. That is, when the cutter 172 is located in the cutter distal recess 176, at least a portion of the cutter 172 is located below the cutter slot distal lip 173, which helps prevent the cutter 172 from accidentally coming out of the cutter slot 175.

[0056] exist Figure 6B 17, the cutter 172 has begun to travel proximally within the cutter body 170 after being initially actuated by the actuator 112 on the handle body 110. The cutter 172 is completely out of the cutter distal recess 176, and a portion of the cutter 172 has emerged from the cutter slot 175. In this position, the cutter 172 is configured to cut tissue as the cutter 172 moves proximally along the cutter track 177. The cutter track 177 is configured to position the cutting edge or cutting surface 184 of the cutter 172 laterally within the cutter slot 175 and also beyond the tissue-facing surface of the cutter body 170.

[0057] exist Figure 6C , cutter 172 has nearly completed its proximal travel within cutter body 170. Figure 6C In the illustrated example, the cutter track 177 positions the same amount of the cutting edge or cutting surface 184 of the cutter 172 outside of the tissue-facing surface of the cutter body 170 as the cutter 172 moves proximally along the cutter track 177. In other examples, the cutter track 177 may be configured to position a greater or lesser portion of the cutting edge or cutting surface 184 of the cutter 172 outside of the tissue-facing surface of the cutter body 170 as the cutter 172 moves proximally along the cutter track 177. In other words, the cutter track 177 may be configured to vary the depth of incision into tissue as the cutter 172 moves proximally along the cutter track 177.

[0058] In some aspects, the depth of the tissue cut ranges from about 2 mm to about 5 mm, including about 2.5 mm, about 3 mm, about 3.5 mm, about 4 mm, or about 4.5 mm, and in some examples, the preferred cutting depth is about 2.5 mm. In some examples, it may be necessary to limit the cutting depth to no more than 5 mm to avoid cutting certain anatomical features that may exist in the area, such as the dorsal vein complex and / or vascular plexus. In some aspects, the length of the incision ranges from about 10 mm to about 50 mm, including about 15 mm, about 20 mm, about 25 mm, about 30 mm, about 35 mm, about 40 mm, or about 45 mm, and in some examples, the preferred incision length is about 20 mm.

[0059] exist Fig.6D 174, the cutter 172 has been moved to the most proximal position within the cutter body 170. At least a portion of the cutter 172 is located within the cutter proximal recess 178, and none of the cutting edges or cutting surfaces 184 of the cutter 172 are exposed to the tissue. The cutter 172 is completely located within the cutter body 170 and below the cutter slot proximal lip 174, which helps prevent the cutter 172 from accidentally coming out of the cutter slot 175 when the cutter 172 is located in the cutter proximal recess 178.

[0060] Fig. 6E is a perspective view of a distal portion of a system according to various aspects of the present disclosure. Fig. 6E The presence of a cutter slot 179 in the distal portion of the cutter body 170 is shown. Fig. 6E 175, the cutter slot 179 is shown as having approximately the same length as the cutter slot 175, but the length of the cutter slot 179 can be greater or less than the length of the cutter slot 175. The width of the cutter slot 179 is preferably at least twice the maximum cutting depth allowed by the characteristic configuration of the cutter body 170. Regardless, the cutter slot 179 should provide sufficient coverage of the cutting area of ​​the tissue. The cutter slot 179 can function as a reservoir for providing an injectable substance so that a sufficient amount of the injectable substance is presented to the treatment target area.

[0061] Fig. 7A and Figure 7B 1 and 2 are plan views of the proximal portion of a system according to various aspects of the present disclosure. Each figure shows that the handle body 110 may include an actuator 112 and a lock 115. Fig. 7A and Figure 7B In the example shown, the lock 115 is a dial or knob that can be moved from a locked position (in Fig. 7A The lock 115 is shown as an indicator portion pointing to the locked indicator 113) to the unlocked position (in Figure 7B14). The lock indicator 113 and the unlock indicator 114 may each use symbols, text, colors, and / or tactile features to indicate to the user the status of the lock 115. The lock 115 interacts with the actuator 112 mechanically, electromechanically, electrically, or in other ways to provide a safety feature that helps prevent accidental actuation of the cutter.

[0062] Fig. 7A and Figure 7B The supply devices connected to the ports on the handle body 110 are shown separately. The inflation supply device 117 is connected to the inflation port 116 and is configured to seal or lock with the inflation port 116 to supply filling fluid to the system to expand the expandable member on the distal portion. Similarly, the injection supply device 119 is connected to the injection port 118 and is configured to seal or lock with the injection port 118 to supply injectable material to the system and through the cutter slot on the distal portion.

[0063] In some examples of the present invention, the handle body includes one or more pressure relief valves, which can be associated with the filling source and / or the injection source. The pressure relief valve can alleviate or help prevent overpressure in the system or tissue. For example, if the filling fluid channel or the injection fluid channel is blocked, the pressure relief valve can release the fluid pressure after the fluid pressure reaches a predetermined threshold, thereby preventing serious damage to the system and / or the patient.

[0064] Fig. 8A and Figure 8B 1 and 2 are perspective views of the proximal portion of the system, showing features on the proximal portion handle body 110 according to various aspects of the present disclosure. Specifically, Fig. 8A Actuator 112 is shown in an initial position corresponding to an initial distal-most position of cutter 172 within cutter body 170, while Figure 8B Actuator 112 is shown in a final position corresponding to a final, proximal-most position of cutter 172 within cutter body 170. Fig. 8A and Figure 8B It is shown that the actuator 112 can be pushed toward the handle body 110 to actuate the cutter movement. The cutter movement can be driven by mechanical, electrical, electromechanical, hydraulic, pneumatic or other forces. In some aspects, the cutter 172 is configured to be reset to its initial position or intermediate position. After resetting, the cutter 172 can be actuated again to make another cut. Optionally, after the device is repositioned to a new treatment target area or rotated within an existing treatment target area, the resetting process can occur multiple times so that additional cuts can be made in the tissue. Repositioning the device may require contracting the expandable member 180.

[0065] Fig. 9A is a flow chart illustrating steps in a method of using a system (e.g., system 100) disclosed herein in accordance with various aspects of the present disclosure. The example method illustrates steps that may be utilized by embodiments of the systems and apparatuses described herein in the specific order shown or in one or more different orders. Fig. 9A Variations of the method shown in and consistent with the remainder of the disclosure may be performed with fewer or more steps.

[0066] As an initial step 300 of the method, a user enters the prostatic urethra by inserting the system into the patient's urethra directly or via an intermediate device (e.g., a channel sheath, an introducer, a guidewire, or a combination thereof) that has been partially placed in the patient's urethra. In a second step 310 of the method, the prostatic urethra and tissue regions therein are visualized using an endoscope connected to the system. The endoscope may be inserted and coupled to the system before the system is inserted into the patient or after the system has been inserted into the patient. The endoscope is connected to a viewing system.

[0067] In the third step 320 of the method, an endoscope connected to the system is used to identify a treatment target. In certain aspects of the present disclosure, the treatment target is a commissure in the prostatic urethra, and in some cases, the target is an anterior commissure in the prostatic urethra. In the fourth step 330 of the method, the cutter body is positioned against the treatment target. Positioning the cutter body may involve rotation of the system (to align the cutter body radially with the treatment target), axial movement of the system (to align the cutter body longitudinally with the treatment target), and / or lateral movement of the system. These movements can be performed in any combination or order. In certain aspects, the user can visualize the prostatic urethra, identify the treatment target, and / or position the cutter body by positioning the endoscope just behind the sphincter so that only the proximal portion of the cutter body is visible.

[0068] Still reference Fig. 9AIn the fifth step 340 of the method, the cutter body is stably fixed to the treatment target. When the cutter body is in the desired position of the treatment target, the expandable member can be expanded to stabilize the cutter body in its position. Alternatively, the cutter body can be positioned near the treatment target but not against the treatment target, so that the expansion of the expandable member moves the cutter body from its position near the treatment target to a position against the treatment target. The user can expand the expansion member using a charging supply device connected to a charging port on the handle body. In one example, the user can press the plunger of the filling fluid injector while viewing the distal portion of the system through an endoscope to ensure the correct positioning and stability of the cutter body relative to the treatment target. In other examples, other imaging methods (such as fluoroscopy) can be used in conjunction with contrast fluid to visualize the expansion of the expandable member and the positioning and stabilization of the cutter body.

[0069] In the sixth step 350 of the method, a cutter is deployed to cut tissue in the treatment target. In one example, the cutter is actuated by a user unlocking a lock on a handle body and pressing an actuator. The cutter moves from its distal position completely within the cutter body to a position where a cutting edge or surface protrudes from the cutter body, then moves proximally to cut tissue of the treatment target, and then reaches a proximal position where the cutting edge or surface is again completely within the cutter body. In some examples, the cutter can be actuated multiple times so that the cutter now moves distally to return to its original position, thereby cutting any tissue in the treatment target it encounters. Further, the cutter can be actuated again so as to pass through the treatment target for the third time, and so on. In some aspects, the cutter is configured to be resettable to its initial position or intermediate position. After resetting, the cutter can be actuated again to perform another cut. Optionally, after the device is repositioned to a new treatment target area or rotated within an existing treatment target area, the resetting process can occur multiple times so that additional cutting can be performed in the tissue. Repositioning the device may require contraction of the expandable member. With the cutter repositioned, the method may loop back to any of steps 310 (visualizing the prostatic urethra), 320 (identifying a treatment target), or 330 (positioning the cutter body).

[0070] Still reference Fig. 9A In a seventh step 360 of the method, one or more therapeutic substances may be administered to the treatment target. Such one or more therapeutic substances may be administered via the cutter slot by an infusion supply device connected to an infusion port on the device handle body. The infusion supply device may contain one or more therapeutic substances, and in some examples, another infusion supply device containing one or more other therapeutic substances may then be connected to the infusion port to administer the one or more other therapeutic substances to the treatment target.

[0071] The therapeutic substance that can be used in the system can be any therapeutic agent or therapeutic substance. In some preferred aspects, the therapeutic substance is a fibrin gel, which can act as a hemostatic agent and tissue scaffold to maintain its physical position and arrangement when the tissue heals. The fibrin gel can be used alone, mixed with other therapeutic substances, or delivered before or after the fibrin gel is applied.

[0072] Examples of particularly useful other substances are lipophilic, substantially water-insoluble drugs, such as paclitaxel, rapamycin, daunorubicin, doxorubicin, lapachone, vitamin D2 and D3 and analogs and derivatives thereof. Other potentially useful drugs include, but are not limited to, glucocorticoids (e.g., dexamethasone, betamethasone), hirudin, angiopeptin, aspirin, growth factors, antisense agents, anticancer agents, antiproliferative agents, oligonucleotides, and more general antiplatelet agents, anticoagulants, antimitotic agents, antioxidants, antimetabolites, antichemotactic agents, and anti-inflammatory agents. Some drugs that are considered to be particularly useful for combating inflammation are corticosteroids, such as budesonide, flunisolide, triamcinolone acetonide, beclomethasone, fluticasone, mometasone, mometasone furoate, dexamethasone, hydrocortisone, methylprednisolone, prednisone, cortisone, betamethasone, triamcinolone acetonide, etc. Also useful are polynucleotides, such as antisense RNA, RNAi or siRNA, which can inhibit inflammation and / or smooth muscle cell or fibroblast proliferation. Antiplatelet drugs include drugs such as aspirin and dipyridamole. Aspirin is an analgesic, antipyretic, anti-inflammatory and antiplatelet drug. Dipyridamole is a drug similar to aspirin that has antiplatelet properties. Dipyridamole is also classified as a coronary vasodilator. Anticoagulants can include drugs such as heparin, protamine, hirudin and tick anticoagulant protein. Antioxidants can include probucol. Antiproliferative drugs include drugs such as amlodipine and doxazosin. Antimitotic and antimetabolite agents that can be used include drugs such as methotrexate, azathioprine, vincristine, vinblastine, 5-fluorouracil, doxorubicin, motamycin. Antibiotic drugs used in this system include penicillin, cefoxitin, oxacillin, tobramycin and gentamicin. Antioxidants suitable for use in this system include probucol. In addition, genes or nucleic acids, or parts thereof, may also be used as therapeutic agents. In addition, collagen synthesis inhibitors such as tranilast may be used as therapeutic agents. Other drugs used in this system also include everolimus, somatostatin, tacrolimus, roxithromycin, dunaimycin, ascomycin, bafilomycin, erythromycin, midecamycin, josamycin, kanamycin, clarithromycin, troleandomycin, foliomycin, cerivastatin, simvastatin, lovastatin, fluvastatin, rosuvastatin, atorvastatin, pravastatin, pitavastatin, vinblastine, vincristine, vindesine, vinorelbine, etoposide, teniposide, nimustine, carmustine, lomustine, cyclophosphamide, 4-hydroxycyclophosphamide, estramustine, melphalan, ifosfamide, trofosfamide, chlorambucil, bendamustine, dacarbazine,Busulfan, procarbazine, trooxosulfan, temozolomide, thiotepa, daunorubicin, doxorubicin, aclarubicin, epirubicin, mitoxantrone, idarubicin, bleomycin, mitomycin, actinomycin, methotrexate, fludarabine, fludarabine-5'-dihydrogen phosphate, cladribine, mercaptopurine, thioguanine, cytarabine, fluorouracil, gemcitabine, capecitabine, docetaxel, carboplatin, cisplatin, oxaliplatin, amsacrine, irinotecan, Topotecan, hydroxyurea, miltefosine, valerate, aldesleukin, retinoic acid, asparaginase, pegaspargase, anastrozole, exemestane, letrozole, formestane, aminoglutethimide, doxorubicin, azithromycin, spiramycin, ceftazidime, smooth muscle cell proliferation inhibitor-2w, epothilone A and B, mitoxantrone, azathioprine, mycophenolate mofetil, c-myc-antisense, b-myc-antisense, betulinic acid, camptothecin, lapachol, β-lapatin Paconone, podophyllotoxin, betulin, podophyllotoxin 2-ethyl hydrazide, morasporatin (rhuGM-CSF), peginterferon a-2b, lenostam (r-HuG-CSF), filgrastim, polyethylene glycol, dacarbazine, basiliximab, daclizumab, selectins (cytokine antagonists), CETP inhibitors, cadherins, mitogen inhibitors, COX-2 inhibitors, NFkB, angiopeptide, ciprofloxacin, Sophora flavescens, flubroxan, monoclonal antibodies that inhibit muscle cell proliferation, bFGF antagonists, probucol, prostaglandins, 1,11-dimethoxycathetin-6-one, 1-hydroxy-11-methoxycathetin-6-one, scopolamine, colchicine, NO donors (e.g., pentaerythritol tetranitrate and synthetic anilines), S-nitroso derivatives, tamoxifen, staurosporine, β-estradiol, α-estradiol, estriol, estrone, ethinyl estradiol,Fosfostil, medroxyprogesterone, estradiol cypionate, estradiol benzoate, tranilast, carbacol and terpenoids for the treatment of cancer, verapamil, tyrosine kinase inhibitors (tyrosine), cyclosporine A, 6-a-hydroxypaclitaxel, baccatin, taxotere and other MCS macrocyclic oligomers and their derivatives, mofebuzone, acemetacin, diclofenac, clonazolac, dapsone, o-aminophenylacetic acid , lidocaine, ketoprofen, mefenamic acid, piroxicam, meloxicam, chloroquine phosphate, penicillamine, hydroxychloroquine, auranofin, sodium aurothiomalate, oxacerol, celecoxib, β-sitosterol, adenosine methionine, myrtocaine, polidocanol, ferulic acid, levmenthol, benzocaine, aescin, ellipticine, D-24851 (antibody), colchicine, cytochalasin AE, indole, nocodazole, S100 protein, rod bacteriocins, vitronectin receptor antagonists, azelastine, guanidine cyclase stimulators, tissue inhibitors of metalloproteinases-1 and -2, free nucleic acids, nucleic acids incorporated with viral delivery materials, DNA and RNA fragments, plasminogen activator inhibitor-1, plasminogen activator inhibitor-2, antisense oligonucleotides, VEGF inhibitors, IGF-1, active agents from the group of antibiotics such as cefadroxil, cefazolin, cefaclor, cefotaxime, tobramycin, gentamicin, penicillins such as dicloxacillin, oxacillin, sulfonamides, metronidazole, antithrombotic agents such as argatroban, aspirin, abciximab, synthetic antithrombin, bivalirudin, warfarin, enoxaparin, desulfated and N-reacetylated heparin, tissue plasminogen activator, GpIIb / IIIa platelet membrane receptor, factor Xa inhibitor antibodies, heparin, hirudin, r-hirudin,PPACK, protamine, prourokinase, streptokinase, warfarin, urokinase, vasodilators such as dipyridine, trapidil, sodium nitroprusside, PDGF antagonists such as triazolopyrimidine and seramin, angiotensin converting enzyme (ACE) inhibitors such as captopril, cilazapril, lisinopril, enalapril, losartan, thiol protease inhibitors, prostacyclin, valpiprost, interferon alpha, beta and gamma, histamine antagonists, serotonin blockers, apoptosis inhibitors, apoptosis modulators such as p65NF-kB or Bcl-xL antisense oligonucleotides, fluge quinolone, nifedipine, tranilast, molsidomide, tea polyphenols, epicatechin gallate, epigallocatechin gallate, boswellic acid and its derivatives, leflunomide, anakinra, etanercept, sulfasalazine, etoposide, dicloxacillin, tetracycline, triamcinolone, motamycin, procainamide, tretinoin, quinidine, disopyramide, flecainide, propafenone, sotalol, amidonone, natural and synthetic steroids (e.g., bryocin A), inotrodiol, majiroside A, galactosides, mannitol, streptococcus glycosides, hydrocortisone, betamethasone, dexamethasone methotrexate, nonsteroidal drugs (NSAIDS) (e.g., fenoprofen), ibuprofen, indomethacin, naproxen, phenylbutyric acid and other antivirals (e.g., acyclovir), ganciclovir and zidovudine, antifungals (e.g., clotrimazole), flucytosine, griseofulvin, ketoconazole, miconazole, nystatin, terbinafine, antiprotozoals (e.g., chloroquine), mefloquine, quinine, natural terpenoids (e.g., sargassum), balintol-C21-angelate, 14-dehydro-herbacin, herbacitracin, herbacitracin, 17-hydroxyherbacin, Ovarian steroids, 4,7-oxocyclobenzoic acid, Bacteroides B1, B2, B3 and B7, Tubei saponins, brucein A, B and C, brucein C, yadazio glycosides N and P, isodeoxyelephanthin, tomentopin A and B, shikonin A, B, C and D, ursolic acid, hyaluronic acid A, yeast protein, isoirone, loganin, erythrin A, erythrin B and C, longifolia flavonoids B, scaponidine C, kamebanine, leucanthin A and B, 13,18-dehydro-6-a-sennecooxychapaline, paclitaxel A and B, regninol, triptolide,In addition, there are serine, apomethacin, aristolochic acid, apomethacin, hydroxyapomethacin, anemonin, proanemonin, berberine, anemonin chloride, cyclotoxin, streptocin, bombastatin A and B, aflatoxin A, curcumin, dihydronickeltitanium, nickeltitanium chloride, 12-β-hydroxypregnene-3,20-dione, bilobal, ginkgo phenol, ginkgolic acid, helenaline, indica glycoside, indica glycoside-N-oxide, pilocarpine, inositol, glycoside 1a, podophyllotoxin, righteousnessin A and B, lalitine, maloterine, maloterial alcohol, isobutyrylmaloterial alcohol, maguire glycoside A, machiantine A, maytansine, lecithin, lycoridine 、Disclatestine, schefflerine, bisphenol A aitidine, oxosuccinine, aristolochic amide All, bisphosphonates, coumarin A, galactosidase, ursolic acid, deoxypsoralen, psychotropic, ricin A, sanguinarine, manwu wheat acid, methyl sorbitol, phosphocholine, stiazoline, manthreonine, streptococcin, aguilin, dihydrousabargin, hydroxyusabargin, strychnine, strychnine, usabargin, usabargin, berberine, schefflerine, oxosuccinine, diphtholone, larch bark, methoxyl larch bark, syringin, umbelliferone, afamosone, acetylvismion B, deacetylvismion A, and vismion A and B. ,

[0073] Fig. 9B is a flowchart illustrating steps in another method of using the system disclosed herein (e.g., system 100) according to various aspects of the present disclosure. The example method illustrates steps that can be used by embodiments of the systems and devices described herein in the particular order described or in one or more different orders. Fig. 9B Variations of the method shown in and consistent with the remainder of the disclosure may be performed with fewer or more steps.

[0074] As an initial step 301 of the method, a user enters the prostatic urethra by inserting the system into the patient's urethra directly or via an intermediate device (e.g., a channel sheath, an introducer, a guidewire, or a combination thereof) that has been partially placed in the patient's urethra. In a second step 311 of the method, an endoscope connected to the system is used to visualize the prostatic urethra and the tissue area therein. In a third step 321 of the method, an endoscope connected to the system is used to identify a treatment target. In a fourth step 331 of the method, the cutter body is positioned against the treatment target. In a fifth step 341 of the method, the cutter body is stabilized against the treatment target. In a sixth step 351 of the method, the cutter is deployed to cut tissue in the treatment target. In a seventh step 356 of the method, acute wound therapy is applied to the treatment target, including but not limited to hot water therapy, light therapy, air therapy, heat therapy, energy therapy (e.g., using radiofrequency energy) to control bleeding and / or otherwise prepare the cut tissue for the next step. The acute wound therapy step is intended to address the acute response of the tissue to the cutting step. In the eighth step 361 of the method, one or more therapeutic substances are applied to the treatment target. In the ninth step 366 of the method, a mechanical stabilizer is applied to the treatment target to maintain the position and / or alignment of the cut tissue. In the case where the cut tissue may heal again or otherwise reverse or weaken the therapeutic effect obtained by cutting the tissue, one or more mechanical stabilizers may be placed in or near the treatment target area, including but not limited to tissue anchors, tissue retractors, implants, stents, catheters, etc. These mechanical stabilizers can be temporary or permanent. In some aspects, it may be necessary to place a catheter in the patient's body, as is commonly done in similar operations.

[0075] Still refer to Fig. 9B In the optional step 336 of the method, the treatment target area can be cleaned by irrigation and / or suction. The optional step 336 can be used once or multiple times in the method and can be used at various points in the method, such as between steps 311 and 321, between steps 321 and 331, between steps 331 and 341, between steps 341 and 351, between steps 351 and 356, and between steps 356 and 361. In some aspects, if the method does not use step 356, the optional step 336 can be used between steps 351 and 361.

[0076] One of the desirable features of the systems and methods disclosed herein is the ability to control the location, depth, and length of incision into tissue. In general, while the systems and methods provide the ability to incise a variety of locations associated with the treatment of BPH, some locations in the anatomy may produce greater therapeutic effects than others. These optimal locations may vary from patient to patient, or may be generally understood. Embodiments of the systems and methods disclosed herein explicitly include determining the desirability of a treatment target location based on a given patient's anatomy, disease state, and other relevant factors.

[0077] Other applications of the system are included in the method of use. For example, it may be desirable to use the system to cut a "hypertonic" bladder neck to allow the patient to urinate more easily. In such a use, Fig. 9A and Fig. 9B The method is applicable.

[0078] Fig.10 4 is a perspective view of another system according to various aspects of the present disclosure. The system 400 is shown coupled to the endoscope body 500 at the proximal end of the handle body 410 of the system 400. The handle body 410 in the illustrated example includes an actuator 412 operably connected to the distal portion 460 of the system 400. Specifically, the actuator 412 can be operatively connected to a deployment or delivery mechanism in the distal portion 460 of the system 400, and thus can be referred to as a "deployment actuator" in various embodiments. The handle body 400 may also include a lock 415 engaged with the actuator 412 to lock or unlock the actuator 412. The lock 415 engages with the actuator 412 to lock it, such that the lock 415 prevents the actuator 412 from being operated when it is in the locked position. Conversely, the lock 415 can be disengaged from the actuator 412 to unlock it and allow the actuator to be operated from the unlocked position.

[0079] exist Fig.10 In the example shown, the lock 415 can be used with Fig. 7A and 7B The lock indicator 413 and the unlock indicator 414 can each use symbols, text, colors and / or tactile features to indicate the state of the lock 415 to the user in a manner similar to the lock 115 shown in FIG. Fig. 7A and 7B The locked indicator 113 and unlocked indicator 114 shown in FIG. 4 are the same or similar. The lock 415 interacts with the actuator 412 mechanically, electromechanically, electrically, or in other ways to provide a safety feature that helps prevent accidental actuation of the delivery mechanism.

[0080] like Fig.10As shown, the handle body 410 may include a filling port 416, which is configured to deliver fluid to the distal portion 460 of the system 400 through a filling cavity in the handle body 410 and in the slender member 450 of the system. The system 400 includes a slender member 450 connecting the handle body 410 and the distal portion 460. The slender member 450 includes an endoscope cavity for the slender portion of the endoscope for use in the patient's body. The slender member 450 also includes the previously described filling cavity. In some examples of the system, the slender member includes an actuation line located in the slender member 450 but separated from the filling cavity. The slender member 450 can be rigid, semi-rigid or semi-flexible. The slender member 450 is configured to be inserted into the urethra of the patient and is composed of a material suitable for medical use.

[0081] Fig.11 is a perspective view of a system according to various aspects of the present disclosure. A filling supply device 417 is connected to the filling port 416 and is configured to seal or lock with the filling port 416 and supply filling fluid to the system to expand the expandable member 480 on the distal portion. In some examples, the handle body may include one or more pressure relief valves, which may be associated with the filling source. The pressure relief valve can alleviate or help prevent overpressure within the system or tissue. For example, if a filling fluid channel is blocked, the pressure relief valve can release the fluid pressure after the fluid pressure reaches a predetermined threshold, thereby preventing damage to the system and / or the patient.

[0082] Fig.10 and Fig.11 The elongated member 450 of the system is shown connected to the distal portion 460 by a hinge 465 (or "hinged portion"). The endoscope distal end 505 can be seen at the distal end of the elongated member 450. In this non-limiting example, the endoscope distal end 505 is a 30 degree cystoscope. Additional endoscopes can be used.

[0083] The hinge 465 is softer than the elongated member 450 and can be configured to be bent at a preformed angle relative to the long axis of the elongated member 450. The preformed curve in the hinge 465 can be configured to roughly match the typical anatomical curvature of the urethra near the prostate and bladder neck. The hinge 465 can be flexible so that the hinge 465 can conform to the curvature of the urethra and position the distal portion 460 in the prostatic urethra without piercing the urethral wall. The hinge 465 enables the distal portion 460 to be easily seen by a 30-degree cystoscope. The hinge 465 can be made of plastic, shape memory material or other flexible to semi-flexible materials suitable for medical use. Compared with a completely rigid device, the flexibility of the hinge 465 allows the urethra to be relatively easier to navigate in addition to allowing the distal portion 460 to present a desired angle relative to the long axis of the elongated member 450 within the anatomical structure. The hinge 465 can include a filling cavity and an actuation line.

[0084] Fig.12 6 is a perspective view of a tissue manipulation structure 600 according to various aspects of the present disclosure. The tissue manipulation structure 600 includes a tissue stabilization member 620, which can be configured to both manipulate and stabilize tissue. The tissue stabilization member 620 can stabilize tissue at the commissures so that the commissures remain open to a greater extent than without the tissue stabilization member 620, such as causing the commissures to remain open for a longer time or to a greater extent than without the tissue stabilization member 620. The stable opening of the commissures in the tissue provides a starting point for the passageway for urine to begin to flow, and then hydraulically opens the remainder of the prostatic urethra. In some aspects, more than one tissue stabilization member 620 can be delivered to the prostatic urethra to manipulate and stabilize tissue and create a portion or all of the flow channel.

[0085] Still refer to Fig.12 , tissue stabilization member 620 may have a length in the range of about 10 mm to about 50 mm, and in some examples, a length in the range of about 25 mm to about 30 mm. In other examples, multiple relatively short length tissue stabilization members 620 may be used with a single elongated member. According to these examples, one or more tissue stabilization members 620 may have a length in the range of about 5 mm to about 15 mm, including a length of about 6 mm, about 7 mm, about 8 mm, about 9 mm, about 10 mm, about 11 mm, about 12 mm, about 13 mm, or about 14 mm. Tissue stabilization member 620 may have a width in the range of about 3 mm to about 10 mm, including a width of about 4 mm, about 5 mm, about 6 mm, about 7 mm, about 8 mm, or about 9 mm, and in some examples, a preferred width is in the range of about 5 mm to about 6 mm.

[0086] Tissue stabilization member 620 may be solid, perforated, porous, or may have some solid portions and some perforated and / or porous portions. Fig.12 A tissue stabilization member 620 is shown having six perforations 625. In some aspects, perforations 625 can promote tissue ingrowth and / or tissue healing. Tissue stabilization member 620 can have a height in the range of about 1 mm to about 3 mm, preferably having a height of about 1 mm.

[0087] Fig.12 It is shown that the tissue manipulation structure 600 may include one or more tissue fixation members 610. Fig.12Eight tissue fixation members 610 present in the tissue manipulation structure 600 are shown. The tissue fixation members 610 can be arranged in the following pattern: there is a group of tissue fixation members 610 on each side of the commissure, each group extends roughly along the longitudinal axis of the prostatic urethra, and each group penetrates the tissue of the prostate lobe. The term "side of the commissure" can refer to a portion of one of the lateral lobes adjacent to form the commissure. Therefore, one group of tissue fixation members 610 can penetrate one lateral lobe, and another group of tissue fixation members 610 can penetrate another lateral lobe. The tissue fixation members 610 in each group can be arranged equidistantly from each other across the tissue stabilization member 620, or the distance between the tissue fixation members 610 across the tissue stabilization member 620 can vary. For example, the two groups of tissue fixation members 610 across the tissue stabilization member 620 can form a "V" shape or a "zigzag" shape or other shapes that can be used to cross the commissure. In some aspects, the tissue fixation members 610 in one group will not directly cross the tissue stabilization member 620 of another group of members. In various aspects of deployment of multiple tissue manipulation structures 600 into the prostatic urethra, the arrangement of tissue fixation members 610 on tissue stabilization members 620 may vary between the multiple tissue manipulation structures 600 .

[0088] The height of the tissue fixation member 610 can be in the range of about 2 mm to about 6 mm, including a height of about 2.5 mm, about 3 mm, about 3.5 mm, about 4 mm, about 4.5 mm, about 5 mm, or about 5.5 mm, and in some examples, a height of about 3 mm is preferred. Therefore, the overall height of the tissue manipulation structure 600 can vary from about 3 mm to about 8 mm, including a total height of 3 mm and 8 mm, and in some examples the total height can preferably be about 4 mm. The tissue fixation member 610 can have a consistent height or an inconsistent height. The height of the tissue fixation member 610 can vary between a group of tissue fixation members 610 and between each group of tissue fixation members 610 in any suitable pattern.

[0089] Tissue fixation member 610 includes one or more features to achieve stable fixation in tissue. Fig.12Such a tissue fixation member 610 is shown, each tissue fixation member 610 has two tissue fixation barbs 612, but there may be more or fewer tissue fixation barbs 612 on each tissue fixation member 610. The number of tissue fixation barbs 612 or any fixation features on a single tissue fixation member 610 may be the same or different than the number of tissue fixation barbs 612 or any fixation features on any other tissue fixation member 610 of the same tissue manipulation structure 600. The tissue fixation barbs 612 may have a different flexibility than the prostate tissue, so that the tissue fixation barbs 612 may bend toward the tissue fixation member 610 when inserted into the tissue, or the tissue fixation barbs 612 may remain stationary when inserted into the tissue. An important aspect of the tissue fixation barbs 612 is that once the tissue is penetrated by the tissue fixation member 610, they may prevent the tissue fixation member 610 from being removed from the tissue.

[0090] In some examples, it may be desirable to limit the depth of penetration into tissue to no greater than about 5 mm to avoid damaging certain anatomical features that may be present in the area, such as the dorsal venous complex and / or vascular plexus.

[0091] Fig.13 and Fig.14 is a perspective view of a distal portion of an example system according to various aspects of the present disclosure. The surface of the transport body 470 facing the tissue to be treated is shown. The transport body 470 includes a transport body cavity 475, from which the tissue manipulation structure 600 can be delivered to the tissue. The transport body cavity 475 is configured to be suitable for the size of delivering one or more tissue manipulation structures 600. Therefore, the transport body cavity 475 can have a length in the range of about 10 mm to about 50 mm, and preferably has a length in the range of about 25 mm to about 30 mm. The transport body cavity 475 can have a width in the range of about 3 mm to about 10 mm, and preferably has a width in the range of about 5 mm to about 6 mm. In addition, the depth of the transport body cavity 475 can vary from about 4 mm to about 10 mm, and in some examples can preferably be about 5 mm deep. The transport body cavity 475 may occupy a substantial portion of the tissue-facing surface of the transport body 470, for example, about 50% of the length of the tissue-facing surface, such as about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, or about 95%, or more.

[0092] The delivery body 470 and the expandable member 480 can work together to place the tissue manipulation structure 600 in the correct position within the prostatic urethra. When the delivery body 470 has been placed in the desired position within the prostatic urethra, the expandable member 480 expands to force the delivery body 470 against the prostatic urethra. The expandable member 480 ensures that there is sufficient contact between the delivery body 470 and the prostatic tissue so that the tissue manipulation structure 600 can be accurately placed around the commissure. The expansion and contraction of the expandable member 480 can be controlled by the filling fluid conducted through the filling cavity from the filling port on the system handle body.

[0093] Fig.15 4 is a partially transparent side view of the distal portion of the system according to various aspects of the present disclosure. As shown, a delivery body mechanism 478 actuated, for example, via an actuation line is used to deliver a tissue manipulation structure 600. In one example, the delivery body mechanism 478 is a ramp feature that forces the tissue manipulation structure 600 to leave the delivery body cavity 475 when it is pulled proximally in the delivery body 470 by the actuation line. It may be necessary to force the tissue manipulation structure 600 to leave the delivery body 470 quickly enough to penetrate the prostate tissue cleanly, for example, to avoid undesirable lateral tearing of the tissue. The delivery motion can be driven by a variety of mechanisms or forces (including mechanical force, electricity, electromechanical force, hydraulic pressure and / or gas pressure). In some aspects, the delivery body mechanism 478 can be configured to be resettable to its initial position or intermediate position. After resetting, the delivery body mechanism 478 can be actuated again to deliver another tissue manipulation structure 600. Optionally, after the device is repositioned to a new treatment target area or an existing treatment target area, the resetting process can occur multiple times so that additional tissue manipulation structures 600 can be placed in the tissue. Repositioning the device may require retracting expandable member 480.

[0094] Fig.16A is a flow chart illustrating steps in a method of using a system (e.g., system 400) disclosed herein in accordance with various aspects of the present disclosure. The example method illustrates steps that may be utilized by embodiments of the systems and apparatuses described herein in the specific order shown or in one or more different orders. Fig.16A Variations of the method shown in and consistent with the remainder of the disclosure may be performed with fewer or more steps.

[0095] As an initial step 700 of the method, a user enters the prostatic urethra by inserting the system into the patient's urethra directly or through an intermediate device (e.g., a channel sheath, an introducer, a guidewire, or a combination thereof) that is partially placed in the patient's urethra. In a second step 710 of the method, an endoscope connected to the system is used to visualize the prostatic urethra and tissue regions therein. The endoscope can be inserted and connected to the system before or after the system has been inserted into the patient's body. The endoscope is connected to the observation system. In a third step 720 of the method, an endoscope connected to the system is used to identify a treatment target. In some aspects of the present disclosure, the treatment target is a commissure in the prostatic urethra, and in some cases, the target is an anterior commissure in the prostatic urethra. In a fourth step 730 of the method, a delivery body is positioned on the treatment target. Positioning the delivery body may involve system rotation (to align the delivery body with the treatment target radially), system axial movement (to align the delivery body with the treatment target longitudinally), and / or system lateral movement. These movements can be performed in any combination or order. In certain aspects, a user can visualize the prostatic urethra, identify a treatment target, and / or position the delivery body by positioning the endoscope just past the sphincter so that only a proximal portion of the delivery body is visible.

[0096] Still reference Fig.16A , in the fifth step 740 of the method, the delivery body is stabilized against the treatment target. When the delivery body is in the desired position of the treatment target, the expandable member can be expanded to stabilize the delivery body in its position. Alternatively, the delivery body can be positioned near the treatment target, but not against the treatment target, so that the expansion of the expandable member moves the delivery body from its position near the treatment target to a position against the treatment target. The user can expand the expander using a charging supply device connected to a charging port on the handle body. In one example, the user can press the plunger of the filling fluid injector while viewing the distal portion of the system through an endoscope to ensure the correct positioning and stabilization of the delivery body relative to the treatment target. In another example, other imaging methods (such as fluoroscopy) can be used in conjunction with contrast fluid to visualize the expansion of the expandable member and the positioning and stabilization of the delivery body.

[0097] In the sixth step 750 of the method, a tissue manipulation structure is deployed to manipulate and stabilize tissue in the treatment target. In one example, the tissue manipulation structure is deployed by the user unlocking the lock on the handle body and pressing the actuator. In some aspects, the actuator is configured to be resettable to its initial position or intermediate position. After resetting, the actuator can be actuated again to deploy another tissue manipulation structure. Optionally, after the device is repositioned to a new treatment target area or rotated within an existing treatment target area, the resetting process can occur multiple times so that additional tissue manipulation structures can be placed in the tissue. Repositioning the device may require contracting the expandable member. In the case of actuator resetting, the method can loop back to any one of steps 710 (visualizing the prostatic urethra), 720 (identifying the treatment target) or 730 (positioning the delivery body).

[0098] Fig. 16B is a flow chart illustrating steps in another method of using the system disclosed herein (e.g., system 400) according to various aspects of the present disclosure. The example method illustrates steps that can be utilized by embodiments of the systems and apparatus described herein in the specific order shown or in one or more different orders. Fig. 16B Variations of the method shown in and consistent with the remainder of the disclosure may be performed with fewer or more steps.

[0099] As an initial step 701 of the method, a user enters the prostatic urethra by inserting the system into the patient's urethra directly or via an intermediate device (e.g., a channel sheath, an introducer, a guidewire, or a combination thereof) that is partially placed in the patient's urethra. In a second step 711 of the method, an endoscope connected to the system is used to visualize the prostatic urethra and tissue regions therein. In a third step 721 of the method, an endoscope connected to the system is used to identify a treatment target. In a fourth step 731 of the method, the delivery body is positioned on the treatment target. In a fifth step 741 of the method, the delivery body is stabilized against the treatment target. In a sixth step 751 of the method, a tissue manipulation structure is deployed to manipulate and stabilize tissue in the treatment target. In a seventh step 756 of the method, acute wound therapy may be applied to the treatment target, including but not limited to hot water therapy, light therapy, air therapy, heat therapy, energy therapy (e.g., using radiofrequency energy) to control bleeding and / or otherwise treat the manipulated tissue. The acute wound therapy step is intended to address acute tissue reactions to the deployment step. In some aspects, it may be necessary to place a catheter inside the patient, as is typically done in similar surgeries.

[0100] Still refer to Fig. 16BIn the optional step 736 of the method, the treatment target area is cleaned by irrigation and / or suction. The optional step 736 can be used once or multiple times in the method and can be used at various points in the method, such as between steps 711 and 721, between steps 721 and 731, between steps 731 and 741, between steps 741 and 751, and between steps 751 and 756.

[0101] One of the desirable features of the systems and methods disclosed herein is the ability to manipulate and stabilize tissue to create fluid pathways. In general, while these systems and methods are capable of manipulating and stabilizing a variety of locations associated with BPH treatment, some locations in the anatomy may produce greater therapeutic effects than other locations. These locations with the best effects may vary from patient to patient, or may be generally understood. The methods disclosed herein are explicitly directed to determining the desirability of a treatment target location based on a particular patient's anatomy, disease state, and other relevant factors.

[0102] Example The detailed description is for illustrative purposes only and is not intended to be limiting. For example, the above examples (or one or more features or components thereof) may be used in combination with each other. System 100 and system 400 may be used, for example, to treat a subject in a certain order. In further embodiments, part or all of the distal portions of system 100 and system 400 may be interchangeable, so that a single device or system may be reversibly coupled to distal portion 160 and distal portion 460 or one or more components thereof (e.g., cutter body 170 and delivery body 470), respectively. Therefore, various features or components have been combined together to simplify the disclosure. This should not be interpreted as an unclaimed disclosed feature being essential to any claim. On the contrary, the subject matter of the invention may be present in all features of a particular disclosed embodiment. Although specific elements, embodiments, and applications of the invention have been shown and described, it should be understood that the invention is not limited thereto, as modifications may be made by those skilled in the art without departing from the scope of the disclosure, particularly in accordance with the foregoing teachings. The following claim examples are hereby incorporated into this detailed description, each of which is independently a separate embodiment: In Example 1, a system for treating a target tissue in a prostatic urethra may include a handle body having a cutter actuator and a charging port, and an elongated member coupled to the distal end of the handle body. The system may also include a cutter body and an expandable member coupled to the distal end of the elongated member. The expandable member may be expanded by a fluid supplied through the charging port by means of the elongated member. The expandable member may be configured to stably abut the cutter body against the target tissue when the expandable member is expanded. The system may also include a cutter configured to move from a first position in the cutter body to a second position protruding from the cutter slot, and to move again to a third position in the cutter body. The movement of the cutter may be controlled by a cutter actuator. The system may also include an injection port on the handle body, the injection port being in fluid communication with the cutter slot via the elongated member. The injection port may be configured to supply a therapeutic substance to the target tissue through the cutter slot.

[0103] In Example 2, the system of Example 1 can optionally be configured such that the handle body is configured to couple with an endoscope.

[0104] In Example 3, the system of either Example 1 or 2 can optionally be configured such that the elongated member includes an endoscope lumen configured to receive the elongated portion of the endoscope.

[0105] In Example 4, the system of any one or any combination of Examples 1-3 can optionally be configured such that the cutter body and the expandable member are coupled to the distal end of the elongated member via a hinge portion.

[0106] In Example 5, the system of Example 4 can be selectively configured such that the hinge portion is configured to bend at a preformed angle relative to the long axis of the slender member.

[0107] In Example 6, the system of either Example 2 or 3 can optionally be configured such that the cutter body is visible through an endoscope.

[0108] In Example 7, the system of any one or any combination of Examples 1-6 can optionally be configured such that the expandable member is configured to stabilize the cutter body against the target tissue by expanding away from the cutter body.

[0109] In Example 8, the system of Example 7 can optionally be configured such that the expandable member engages tissue when expanded.

[0110] In Example 9, the system of any one of Examples 1-8 or any combination thereof can optionally be configured such that the cutter slot is positioned along a long axis of the cutter body.

[0111] In Example 10, the system of any one or any combination of Examples 1-9 can optionally be configured such that the cutter is configured to move in a distal to proximal direction.

[0112] In Example 11, the system of any one or any combination of Examples 1-10 can optionally be configured such that the cutter is configured to move in a proximal to distal direction.

[0113] In Example 12, the system of any one or any combination of Examples 1-11 can optionally be configured to further include at least one cutter recess in the cutter body, wherein the cutter is configured to be completely located within the cutter body when at least a portion of the cutter is located in the cutter recess.

[0114] In Example 13, the system of Example 12 can optionally be configured such that the at least one cutter groove includes two cutter grooves.

[0115] In Example 14, the system of Example 13 can optionally be configured such that the two cutter grooves include a distal cutter groove and a proximal cutter groove.

[0116] In Example 15, the system of Example 14 can optionally be configured to further include a cutter track located between the distal cutter recess and the proximal cutter recess.

[0117] In Example 16, the system of Example 15 can optionally be configured such that the cutter track is configured to position the cutting edge of the cutter beyond the tissue-facing surface of the cutter body.

[0118] In Example 17, the system of Example 16 can optionally be configured such that the cutter track is configured to vary the depth of incision into tissue as the cutter moves along the cutter track.

[0119] In Example 18, the system of any one of Examples 1-17 or any combination thereof can optionally be configured to further include a cutter wire coupled between the cutter actuator and the cutter.

[0120] In Example 19, the system of Example 18 can optionally be configured such that the cutter wire is located within the elongated member.

[0121] In Example 20, the system of Example 19 can optionally be configured such that the cutter wire is positioned within a cutter wire lumen within the elongated member.

[0122] In Example 21, the system of Example 20 can optionally be configured such that the cutter wire lumen is in fluid communication with the injection port.

[0123] In Example 22, the system of Example 21 can optionally be configured such that the cutter line lumen is configured to transfer fluid from the injection port to the cutter slot.

[0124] In Example 23, a method for treating tissue in a target area of ​​the prostatic urethra may involve accessing the prostatic urethra using a treatment system. The system may include a handle body having a cutter actuator and a charging port, and an elongated member coupled to the distal end of the handle body. The system may also include a cutter body and an expandable member coupled to the distal end of the elongated member. The expandable member may be expanded by a fluid supplied through the charging port by means of the elongated member, and the expandable member may be configured to stabilize the cutter body against the target area during expansion. The system may also include a cutter configured to move from a first position in the cutter body to a second position protruding from the cutter slot, and again to a third position in the cutter body. The movement of the cutter may be controlled by a cutter actuator. The system may also include an injection port located on the handle body, the injection port being in fluid communication with the cutter slot through the elongated member. The injection port may be configured to supply a therapeutic substance to the target area through the cutter slot.

[0125] In Example 24, the method of Example 23 may further optionally involve stabilizing the cutter body against a target area in the prostatic urethra.

[0126] In Example 25, the method of any of Examples 23 or 24 may further optionally involve cutting tissue in the prostatic urethra by movement of the cutter.

[0127] In Example 26, the method of any one of Examples 23-25 ​​or any combination thereof may also optionally involve administering a therapeutic substance to the target area through the cutter slot.

[0128] In Example 27, the method of any one of Examples 23-26 or any combination thereof may also optionally involve visualizing the target area in the prostatic urethra using an endoscope coupled to the system.

[0129] In Example 28, the method of any one of Examples 23-26 or any combination thereof may also optionally involve identifying tissue to be cut in the prostatic urethra using an endoscope coupled to the system.

[0130] In Example 29, the method of any one of Examples 23-28 or any combination thereof can optionally be implemented such that the target region includes a commissure.

[0131] In Example 30, the method of any one or any combination of Examples 23-29 can be optionally implemented so that the therapeutic substance includes one or more hemostatic agents, antiproliferative agents, antiplatelet agents, anticoagulants, antimitotic agents, antioxidants, anti-metabolic agents, anti-chemotactic agents, anti-inflammatory agents, or a combination thereof.

[0132] In Example 31, the method of any one of Examples 23-30 or any combination thereof can optionally be implemented such that the therapeutic substance comprises a fibrin gel.

[0133] In example 32, a system for treating a target tissue in a prostatic urethra may include a handle body having a deployment actuator and a charging port, and an elongated member coupled to the distal end of the handle body. The system may also include a conveying body and an expandable member coupled to the distal end of the elongated member. The expandable member may be expanded by a fluid supplied by means of the elongated member through the charging port. The expandable member may be configured to stably abut the conveying body against the target tissue when it expands. The system may also include a tissue manipulation structure configured to move from a first position in the conveying body to a second position at least partially in the prostatic tissue. The movement of the tissue manipulation structure may be controlled by the deployment actuator.

[0134] In Example 33, the system of Example 32 can optionally be configured such that the tissue manipulation structure includes a tissue stabilization member coupled to the tissue fixation member.

[0135] In Example 34, the system of either Example 32 or 33 can optionally be configured such that the tissue manipulation structure includes a tissue stabilization member coupled to a plurality of tissue fixation members.

[0136] In Example 35, the system of either Example 33 or 34 can optionally be configured such that the tissue fixation member includes one or more tissue fixation barbs.

[0137] In Example 36, the system of any one or any combination of Examples 33-35 can optionally be configured such that the tissue stabilization member is completely solid.

[0138] In Example 37, the system of any one or any combination of Examples 33-35 can optionally be configured such that the tissue stabilization member is at least partially perforated or porous.

[0139] In Example 38, the system of any one or any combination of Examples 32-37 can optionally be configured such that the handle body is configured to couple with an endoscope.

[0140] In Example 39, the system of any one or any combination of Examples 32-38 can optionally be configured such that the elongated member includes an endoscope lumen configured to receive the elongated portion of the endoscope.

[0141] In Example 40, the system of any one or any combination of Examples 32-39 can optionally be configured such that the delivery body and the expandable member are coupled to the distal end of the elongated member via a hinge portion.

[0142] In Example 41, the system of Example 40 can be selectively configured such that the hinge portion is configured to bend at a preformed angle relative to the long axis of the slender member.

[0143] In Example 42, the system of either Example 40 or 41 can optionally be configured such that the delivery body is visible through an endoscope.

[0144] In Example 43, the system of any one of Examples 32 to 42 or any combination thereof can optionally be configured such that the expandable member is configured to stabilize the delivery body against the target tissue by expanding away from the delivery body.

[0145] In Example 44, the system of Example 43 can optionally be configured such that the expandable member engages tissue when expanded.

[0146] In Example 45, the system of any one of Examples 32 to 44 or any combination thereof can optionally be configured to further include an actuation wire coupled between the deployment actuator and the delivery body mechanism.

[0147] In Example 46, the system of Example 45 can optionally be configured such that the actuation wire is located within the elongated member.

[0148] In Example 47, the system of Example 46 can optionally be configured such that the actuation wire is positioned within an actuation wire lumen within the elongated member.

[0149] In Example 48, the system of any one of Examples 45 to 47 or any combination thereof can optionally be configured such that the delivery body mechanism is configured to move the tissue manipulation structure from the first position to the second position.

[0150] In Example 49, the system of Example 48 can optionally be configured such that the delivery body mechanism is configured to be resettable.

[0151] In example 50, a method for treating tissue in a target area of ​​the prostatic urethra may involve accessing the prostatic urethra using a treatment system. The system may include a handle body having a deployment actuator and a charging port, and an elongated member coupled to the distal end of the handle body. The system may also include a conveying body and an expandable member coupled to the distal end of the elongated member. The expandable member may be expanded by a fluid supplied by the elongated member through the charging port, and the expandable member may be configured to stabilize the conveying body against the target area when the expandable member is expanded. The system may also include a tissue manipulation structure configured to move from a first position in the conveying body to a second position at least partially in the prostatic tissue. The movement of the tissue manipulation structure may be controlled via the deployment actuator.

[0152] In Example 51, the method of Example 50 may also optionally involve stabilizing the delivery body against a target area in the prostatic urethra.

[0153] In Example 52, the method of any of Examples 50 or 51 may further optionally involve deploying a tissue manipulation structure to manipulate and stabilize tissue in the target area.

[0154] In Example 53, the method of any one of Examples 50-52 or any combination thereof may also optionally involve visualizing a target area in the prostatic urethra using an endoscope coupled to the system.

[0155] In Example 54, the method of any one of Examples 50-52 or any combination thereof may also optionally involve identifying a target area in the prostatic urethra using an endoscope coupled to the system.

[0156] In Example 55, the method of any one of Examples 50-54 or any combination thereof can optionally be implemented such that the target region includes a commissure.

[0157] Conclusion This patent document uses some terms to refer to specific features or components. It is understood by those skilled in the art that different people may use different names to refer to the same feature or component. This patent document is not intended to distinguish components or features that have different names but the same function.

[0158] For the following defined terms, the defined definitions shall be adopted unless different definitions are given elsewhere in this patent document. The terms "one", "an" and "the" are used to include one or more, independent of any other instances or usages of "at least one" or "one or more". The term "or" is used to represent a non-exclusive or, for example, "A or B" includes "A but not B", "B but not A" and "A and B". All numerical values ​​are assumed to be modified by the term "about", whether or not explicitly stated. The term "about" generally refers to a numerical range that is considered by those skilled in the art to be equivalent to the value (e.g., having the same function or result). In many cases, the term "about" may include rounding to the nearest significant figure. The numerical range expressed by the endpoints includes all numbers and sub-ranges within and bounded by the range (e.g., 1 to 4 includes 1, 1.5, 1.75, 2, 2.3, 2.6, 2.9, etc., as well as 1 to 1.5, 1 to 2, 1 to 3, 2 to 3.5, 2 to 4, 3 to 4, etc.). The terms "patient" and "subject" are intended to include mammals, eg, for human or veterinary applications.

[0159] The scope of the present invention should be determined by reference to the appended claims, along with the full scope of equivalents to which such claims are entitled. In the appended claims, the terms "including" and "wherein" are used as the plain-English equivalents of the respective terms "comprising" and "characterized by." Furthermore, in the following claims, the terms "including" and "comprising" are open-ended; that is, devices, kits, or methods that include additional features or components in addition to those listed after such terms in the claims are still deemed to fall within the scope of the claims. Furthermore, in the following claims, the terms "first," "second," "third," etc. are used merely as labels and are not intended to impose numerical requirements on their objects.

[0160] The abstract of the specification is intended to allow readers to quickly understand the nature of the technical disclosure. It should be submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the claims.

Claims

1. A system for treating target tissue in the prostatic urethra, include: a handle body having a cutter actuator and a fill port; an elongated member coupled to the distal end of the handle body; a cutter body and an expandable member coupled to the distal end of the elongated member, wherein the expandable member is expandable by a fluid supplied through the inflation port by means of the elongated member, and the expandable member is configured to stabilize the cutter body against the target tissue when the expandable member is expanded; a cutter configured to move from a first position within the cutter body to a second position protruding from the cutter slot and again to a third position within the cutter body, wherein movement of the cutter is controlled via a cutter actuator; as well as An injection port is located on the handle body and is in fluid communication with the cutter slot via the elongated member, wherein the injection port is configured to supply a therapeutic substance to a target tissue through the cutter slot.

2. The system of claim 1, wherein the handle body is configured to couple with an endoscope.

3. The system of claim 1, wherein the elongated member comprises an endoscope lumen configured to receive the elongated portion of an endoscope.

4. The system of any one of claims 1 to 3, wherein the cutter body and the expandable member are coupled to the distal end of the elongated member via a hinge portion.

5. The system of claim 4, wherein the hinge portion is configured to bend at a preformed angle relative to the long axis of the slender member.

6. The system of claim 2 or 3, wherein the cutter body is visible through an endoscope.

7. The system of any of the preceding claims, wherein the expandable member is configured to stabilize the cutter body against the target tissue by expanding away from the cutter body.

8. The system of claim 7, wherein the expandable member engages tissue when expanded.

9. The system of any of the preceding claims, wherein the cutter slot is located along a long axis of the cutter body.

10. The system of any of the preceding claims, wherein the cutter is configured to move in a distal to proximal direction.

11. The system of any of the preceding claims, wherein the cutter is configured to move in a proximal to distal direction.

12. The system of any of the preceding claims, further comprising at least one cutter recess located in the cutter body, wherein the cutter is configured to be completely located within the cutter body when at least a portion of the cutter is positioned in the cutter recess.

13. The system of claim 12, wherein the at least one cutter groove comprises two cutter grooves.

14. The system of claim 13, wherein the two cutter recesses include a distal cutter recess and a proximal cutter recess.

15. The system of claim 14, further comprising a cutter track located between the distal cutter recess and the proximal cutter recess.

16. The system of claim 15, wherein the cutter track is configured to position the cutting edge of the cutter beyond the tissue-facing surface of the cutter body.

17. The system of claim 16, wherein the cutter track is configured to vary the depth of incision into tissue as the cutter moves along the cutter track.

18. The system of any one of the preceding claims, further comprising a cutter wire coupled between the cutter actuator and the cutter.

19. The system of claim 18, wherein the cutter wire is located within the elongated member.

20. The system of claim 19, wherein the cutter wire is positioned within a cutter wire lumen within the elongated member.

21. The system of claim 20, wherein the cutter line lumen is in fluid communication with the injection port.

22. The system of claim 21, wherein the cutter line lumen is configured to transfer fluid from the injection port to the cutter slot.

23. A method for treating tissue in a target region of the prostatic urethra, include: Accessing the prostatic urethra with a treatment system comprising a handle body having a cutter actuator and a fill port; an elongated member coupled to the distal end of the handle body; a cutter body and an expandable member coupled to the distal end of the elongated member, wherein the expandable member is expandable by a fluid supplied through the inflation port by means of the elongated member, and the expandable member is configured to stabilize the cutter body against the target area when the expandable member is expanded; a cutter configured to move from a first position in the cutter body to a second position protruding from the cutter recess and again to a third position in the cutter body, wherein movement of the cutter is controlled via a cutter actuator; as well as An injection port is located on the handle body and is in fluid communication with the cutter recess through the elongated member, wherein the injection port is configured to deliver a therapeutic substance to a target area through the cutter recess.

24. The method of claim 23, further comprising stabilizing the cutter body against a target area in the prostatic urethra.

25. The method of claim 23 or 24, further comprising cutting tissue in the prostatic urethra by movement of the cutter.

26. The method of any one of claims 23 to 25, further comprising administering a therapeutic substance to the target area through the cutter slot.

27. The method of any one of claims 23 to 26, further comprising visualizing a target area in the prostatic urethra using an endoscope coupled to the system.

28. The method of any one of claims 23 to 26, further comprising identifying tissue to be cut in the prostatic urethra using an endoscope coupled to the system.

29. The method of any one of claims 23 to 28, wherein the target area comprises a commissure.

30. The method of any one of claims 23 to 29, wherein the therapeutic substance comprises one or more hemostatic agents, antiproliferative agents, antiplatelet agents, anticoagulants, antimitotic agents, antioxidants, antimetabolites, antichemotactic agents, anti-inflammatory agents, or combinations thereof.

31. The method of claim 30, wherein the therapeutic substance comprises a fibrin gel.

32. A system for treating target tissue in the prostatic urethra, include: a handle body having a deployment actuator and a filling port; an elongated member coupled to the distal end of the handle body; a delivery body and an expandable member coupled to the distal end of the elongated member, wherein the expandable member is expandable by a fluid supplied through the inflation port via the elongated member, and the expandable member is configured to stabilize the delivery body against the target tissue when the expandable member is expanded; as well as A tissue manipulation structure is configured to move from a first position within the delivery body to a second position at least partially within prostate tissue, wherein movement of the tissue manipulation structure is controlled by the deployment actuator.

33. The system of claim 32, wherein the tissue manipulation structure comprises a tissue stabilization member coupled to the tissue fixation member.

34. The system of claim 32, wherein the tissue manipulation structure comprises a tissue stabilization member coupled to a plurality of tissue fixation members.

35. The system of claim 33 or 34, wherein the tissue fixation member comprises one or more tissue fixation barbs.

36. The system of any one of claims 33 to 35, wherein the tissue stabilization member is completely solid.

37. The system of any one of claims 33 to 35, wherein the tissue stabilization member is at least partially perforated or porous.

38. The system of any one of claims 32 to 37, wherein the handle body is configured to couple with an endoscope.

39. The system of any one of claims 32 to 37, wherein the elongate member comprises an endoscope lumen configured to receive an elongate portion of an endoscope.

40. The system of any one of claims 32 to 39, wherein the delivery body and the expandable member are coupled to the distal end of the elongate member via a hinge portion.

41. The system of claim 40, wherein the hinge portion is configured to bend at a preformed angle relative to the long axis of the slender member.

42. The system of claim 40 or 41, wherein the delivery body is endoscopically visible.

43. The system of any one of claims 32 to 42, wherein the expandable member is configured to stabilize the delivery body against the target tissue by expanding away from the delivery body.

44. The system of claim 43, wherein the expandable member engages tissue when the expandable member is expanded.

45. The system of any one of claims 32 to 44, further comprising an actuation wire coupled between the deployment actuator and the delivery body mechanism.

46. ​​The system of claim 45, wherein the actuation wire is located within the elongated member.

47. The system of claim 46, wherein the actuation wire is located within an actuation wire lumen within the elongated member.

48. The system of any one of claims 45 to 47, wherein the delivery body mechanism is configured to move the tissue manipulation structure from a first position to a second position.

49. The system of claim 48, wherein the delivery body mechanism is configured to be resettable.

50. A method of treating tissue in a target region of the prostatic urethra, include: The prostatic urethra is accessed using a treatment system comprising: a handle body having a deployment actuator and a filling port; an elongated member coupled to the distal end of the handle body; a delivery body and an expandable member coupled to the distal end of the elongated member, wherein the expandable member is expandable by a fluid supplied through the inflation port by means of the elongated member, and the expandable member is configured to stabilize the delivery body against the target area when the expandable member is expanded; and A tissue manipulation structure is configured to move from a first position within the delivery body to a second position at least partially within prostate tissue, wherein movement of the tissue manipulation structure is controlled by the deployment actuator.

51. The method of claim 50, further comprising stabilizing the delivery body against a target area in the prostatic urethra.

52. The method of claim 50 or 51 further comprising deploying a tissue manipulation structure to manipulate and stabilize tissue in the target area.

53. The method of any one of claims 50 to 52, further comprising visualizing a target area in the prostatic urethra using an endoscope coupled to the system.

54. The method of any one of claims 50 to 52, further comprising identifying a target area in the prostatic urethra using an endoscope coupled to the system.

55. The method of any one of claims 50 to 54, wherein the target area comprises a commissure.